Anzeige
Mehr »
Login
Sonntag, 19.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
100-Milliarden-Dollar-Marke: Wie die strategische Vision eines Unternehmens historischem Meilenstein passt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
787 Leser
Artikel bewerten:
(2)

Royal DSM: DSM starts construction of large scale production facility for its novel methane-reducing feed additive for ruminants, Bovaer in Dalry, Scotland

Finanznachrichten News

HEERLEN, Netherlands, Nov. 30, 2022 /PRNewswire/ -- Royal DSM, a global purpose-led science-based company active in Health, Nutrition and Bioscience, today began construction of a new manufacturing facility at its site in Dalry, Scotland. The plant will significantly increase global production of Bovaer, DSM's unique methane-reducing feed additive for cattle. In an official groundbreaking ceremony attended by the First Minister of Scotland, Nicola Sturgeon, and Dimitri de Vreeze, Co-CEO of DSM, the company marked the next step in its plan to use Bovaer to reduce global methane emissions and contribute to worldwide methane reduction targets.

DSM Logo.

DSM announced that planning had started during the UN Climate Change Conference last year in Glasgow. Construction officially began today on a facility that will help DSM scale-up production of Bovaer in the coming years and marks another milestone in the company's ambition to bring its methane-reducing feed additive to the market worldwide. This development of DSM's Dalry site has been supported by the Scottish Government through Scottish Enterprise, the national agency supporting economic development and innovation.

Reducing methane emissions is crucial for keeping warming below the 1.5°C target outlined in the Paris Agreement. Over 100 countries have signed a Global Methane Pledge, agreeing to reduce global methane emissions by at least 30% by 2030. The addition of new signatories in recent months, such as Australia in October 2022, underscores growing recognition of the need for urgent action. Ruminants (mainly cows) emit around 20% of all methane gasses globally, so reducing emissions in ruminant herds will play a vital role in meeting global climate ambitions.

Bovaer is a feed additive that can achieve an average enteric methane reduction of 30% in dairy cows, and 45% in beef cattle (with some tests showing reductions of up to 90%). DSM has initial product volumes available for near term market development. The product is in the early commercialization phase in many countries around the world, including the EU/EEA, Argentina, Australia, Brazil, Chile, Pakistan, Switzerland, Turkey, and Uruguay. Since the start of the development of Bovaer an estimate of 15,000 tons of CO2e has been saved, and reductions will accelerate further once the Dalry plant is fully operational, expected in the course of 2025.

Rt Hon Nicola Sturgeon MSP, First Minister of Scotland, said: "Just one year on from the announcement at COP26, I am very pleased to see the progress being made on site and the fact that spades are now in the ground.

We are here today to celebrate a world-leading project and multi-million pound investment which will make Scotland the home of this innovative product, underlining that Scotland continues to lead the way in delivering a net zero future."

Dimitri de Vreeze, Co-CEO of DSM, commented: "After many years of hard work and dedication, it's a wonderful feeling to attend the groundbreaking ceremony for such a large-scale production facility. This is a historic moment for DSM: We are continuing to deliver on our 2030 methane pledge, one of our food systems commitments. I wish the construction team every success as they develop this plant in the coming years."

Scottish Enterprise's Chief Executive, Adrian Gillespie, added: "Today's groundbreaking ceremony is a significant milestone and the next step in delivering such an innovative project for Ayrshire and Scotland.

Royal DSM's Project Bovaer has the potential to be a game-changer for emissions reductions from cattle. Scottish Enterprise has developed a close relationship with Royal DSM over many years and we were delighted to work with the company to secure Dalry as the home for this global manufacturing opportunity."

About Bovaer
Bovaer is a feed additive for cows researched and developed over 10 years by DSM. Just a quarter teaspoon of Bovaer per cow per day consistently reduces enteric methane emission by on average 30% for dairy cows on average 45% for beef cattle. The feed additive Bovaer therefore contributes to a significant and immediate reduction of the environmental footprint of meat, milk and dairy products. Bovaer is the most extensively studied and scientifically proven solution to the challenge of burped methane to date. Upon feeding, it takes effect immediately.

About DSM in Dalry
DSM is one of the region's most prominent companies, employing over 400 staff and around 150 to 200 contractors at the Dalry production facility situated in North Ayrshire, 25 miles south-west of Glasgow. The site has been producing vitamins since 1958 and today the main production processes are Vitamin C, Calcium-D-Pantothenate (vitamin B5) and Panthenol (proVitamin B5).

All our vitamin forms produced at the Dalry facility serve the highly varied needs of the human and animal nutrition and health sectors, as well as the pharmaceutical industry and personal care industries.

The Dalry site is fully committed to sustainability for the future. We have delivered significant investment to demonstrate continued reduction of our CO2 emissions, which has focused on technology improvements within our production processes and utilities operations. This work continues to identify further continuous improvement activity alongside development of step change opportunities.

DSM
Royal DSM is a global, purpose-led company in Health, Nutrition & Bioscience, applying science to improve the health of people, animals and the planet. DSM's purpose is to create brighter lives for all. DSM's products and solutions address some of the world's biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders - customers, employees, shareholders, and society at large. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at www.dsm.com.

Or find us on:

LinkedIn: http://www.linkedin.com/company/3108
Twitter: http://www.twitter.com/DSM
Facebook: http://www.facebook.com/DSMcompany
YouTube: http://www.youtube.com/user/dsmcompany

For more information

DSM Animal Nutrition & Health

Mirelle van der Kreeft

tel. +31 (0) 6 10381639

email mirelle.kreeft-van-der@dsm.com

DSM Investor Relations

Dave Huizing

tel. +31 (0) 45 5782864

email investor.relations@dsm.com

Logo - https://mma.prnewswire.com/media/329419/dsm_logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/dsm-starts-construction-of-large-scale-production-facility-for-its-novel-methane-reducing-feed-additive-for-ruminants-bovaer-in-dalry-scotland-301689684.html

© 2022 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.